Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 12, No. 12, 1425-1432, December 2007; doi:10.1634/theoncologist.12-12-1425
© 2007 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Neil, B. H.
Right arrow Articles by Venook, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Neil, B. H.
Right arrow Articles by Venook, A. P.

Hepatobiliary

Hepatocellular Carcinoma: The Role of the North American GI Steering Committee Hepatobiliary Task Force and the Advent of Effective Drug Therapy

Bert H. O'Neila, Alan P. Venookb

aUniversity of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA; bUniversity of California at San Francisco Comprehensive Cancer Center, San Francisco, California, USA

Key Words. Hepatocellular carcinoma • Liver neoplasms • Chemoembolization • Drug therapy • Doxorubicin • Sorafenib • Bevacizumab • Erlotinib

Correspondence: Bert H. O'Neil, M.D., University of North Carolina Lineberger Comprehensive Cancer Center, 101 Manning Drive, 3009 Old Clinic Building, Chapel Hill, North Carolina 27599, USA. Telephone: 919-966-4431; Fax: 919-966-6735; e-mail: bert_oneil{at}med.unc.edu

Disclosure: B.H.O'N. has acted as a consultant to Bayer. No other potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Hepatocellular carcinoma (HCC) is a disease that requires multidisciplinary management. There has been no widely accepted standard for systemic therapy for this disease until recently. This article briefly discusses the management of earlier stage HCC, then focuses on newer agents with promise, particularly sorafenib, a drug that appears to be the new standard of care for advanced disease.




This article has been cited by other articles:


Home page
 Anticancer ResHome page
Y. YEN, S. SO, M. ROSE, M. W. SAIF, E. CHU, S.-H. LIU, A. FOO, Z. JIANG, T. SU, and Y.-C. CHENG
Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma
Anticancer Res, October 1, 2009; 29(10): 4083 - 4092.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. K. Yoo, R. Gredler, N. Vozhilla, Z.-z. Su, D. Chen, T. Forcier, K. Shah, U. Saxena, U. Hansen, P. B. Fisher, et al.
Identification of genes conferring resistance to 5-fluorouracil
PNAS, August 4, 2009; 106(31): 12938 - 12943.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. J. M. Siemerink, N. H. Mulder, A. H. Brouwers, and G. A. P. Hospers
18F-Fluorodeoxyglucose Positron Emission Tomography for Monitoring Response to Sorafenib Treatment in Patients with Hepatocellular Carcinoma
Oncologist, June 1, 2008; 13(6): 734 - 735.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2007 by AlphaMed Press.
Advertisement